Glycosphingolipid antigens and cancer therapy.
Specific types of glycosphingolipid (GSL), which are chemically detectable in normal cells, are more highly expressed in tumors. The high level of expression on the surfaces of tumor cells causes an antibody response to these GSLs, which can therefore be described as tumor-associated antigens. Some of these GSLs have been shown to be adhesion molecules involved in tumor cell metastasis, and to be modulators of signal transduction controlling tumor cell growth and motility. Tumor-associated GSL antigens have been used in the development of antitumor vaccines. GSLs and sphingolipids involved in adhesion and signaling are therefore targets for cancer therapy.
Hakomori
S
S
Pacific Northwest Research Foundation, Biomembrane Division, University of Washington, 720 Broadway, Seattle, WA 98122, USA. hakomori@u.washington.edu
Zhang
Y
Y
D000818:Animals; D000951:Antigens, Neoplasm / Q000627:therapeutic use*; D019496:Cancer Vaccines; D002240:Carbohydrate Sequence; D002448:Cell Adhesion; D006028:Glycosphingolipids / Q000627:therapeutic use*; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D015398:Signal Transduction
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D006028:Glycosphingolipids